| Literature DB >> 24472655 |
Zhe Qu, Fanjun Meng, Hui Zhou, Jilong Li, Quanhui Wang, Fan Wei, Jianlin Cheng, C Michael Greenlief, Dennis B Lubahn, Grace Y Sun, Siqi Liu, Zezong Gu1.
Abstract
BACKGROUND: Nitric oxide (NO) is a signaling molecule regulating numerous cellular functions in development and disease. In the brain, neuronal injury or neuroinflammation can lead to microglial activation, which induces NO production. NO can react with critical cysteine thiols of target proteins forming S-nitroso-proteins. This modification, known as S-nitrosylation, is an evolutionarily conserved redox-based post-translational modification (PTM) of specific proteins analogous to phosphorylation. In this study, we describe a protocol for analyzing S-nitrosylation of proteins using a gel-based proteomic approach and use it to investigate the modes of action of a botanical compound found in green tea, epigallocatechin-3-gallate (EGCG), on protein S-nitrosylation after microglial activation. METHODS/Entities:
Mesh:
Substances:
Year: 2014 PMID: 24472655 PMCID: PMC3922161 DOI: 10.1186/1742-2094-11-17
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Figure 1Development of NitroDIGE to detect SNO-proteins. (A) Schematic showing the NitroDIGE method for labeling of S-nitrosylated cysteine thiols. A hypothetical protein is indicated with cysteines in the free thiol, disulfide, or nitrosothiol conformation. Free thiols are first blocked with MMTS. Ascorbate selectively releases NO from S-nitrosylated cysteine thiols. The fluorescent thiol-reactive CyDye™ (Cy3 or Cy5) reacts with NO-released thiols to form stable fluorescent complexes. (B) The specificity and sensitivity of NitroDIGE. (a) Cell lysates (20 μg) were treated with 200 μM SNOC, and SNO-proteins were analyzed by NitroDIGE; 5 μg of proteins from each NitroDIGE-labeled sample were separated by SDS-PAGE and Cy5 fluorescence signals were collected. Control omitting SNOC, MMTS, ascorbate, or Cy5 demonstrated that CyDye™ specifically labeled SNO-proteins. (b) In the BST, 250 μg of SNO-proteins were labeled with Biotin-HPDP, pulled down by avidin-agarose, and visualized by silver staining. (C) BV-2 cell lysates were exposed to different doses of SNOC as a test of sensitivity. The NitroDIGE method detected SNO-proteins in cell lysates treated with as low as 10 μM SNOC.
Figure 2Identification and quantification of SNOC-induced protein -nitrosylation in BV-2 cells by NitroDIGE. (A) Workflow of NitroDIGE to identify and quantify SNO-proteins. Pooled internal standard and individual samples are labeled with Cy3 and Cy5, respectively, and subjected to 2-DE. 2-DE gel fluorescence is detected using a Fuji 5000 scanner and quantified by the SameSpots software. On a corresponding zinc-staining gel, selected fluorescence intensity-differential spots are excised for MS analysis. (B) NitroDIGE analysis of protein S-nitrosylation in ex vivo SNOC-treated BV-2 cells. Following the work flow above, untreated control and SNOC-treated samples in biological triplicate were labeled with CyDye™ and resolved on six different gels. A representative gel from each group is shown. (C) Quantitative analysis with the SameSpots software revealed 47 spots with significant fluorescence intensity changes between SNOC-treated and untreated control samples (fold change >1.3, P <0.05). (D) Quantification results for spot #43 are displayed as an example.
Figure 3LPS-induced protein -nitrosylation in BV-2 cells. (A) LPS-induced NO production. BV-2 cells were treated or untreated with 100 ng/mL LPS for 12, 16, or 20 hours. A Griess assay indicated NO production was elevated in the conditioned medium as the LPS incubation time increased. (B) NitroDIGE analysis of protein S-nitrosylation in BV-2 cells treated with LPS for 20 hours. Compared to untreated control, more green spots were seen from LPS-treated sample on the 2-DE gel. (C) Quantitative analysis revealed a total of 16 spots with significant S-nitrosylation level changes (fold change >1.3, P <0.05), from which 13 unique proteins were identified (Additional file 3: Table S2).
Figure 4Effect of EGCG on LPS-induced protein -nitrosylation in BV-2 cells. (A) Dose titration for EGCG. BV-2 cells were treated with 0, 5, 10, and 20 μM EGCG for 20 hours and cell viability was assessed by a MTT assay (# P <0.01, control vs. 20 μM EGCG, n = 3). (B) Administration of EGCG (10 μM) 1 hour prior to LPS (100 ng/mL) exposure inhibited NO production in BV-2 cells (# P <0.01, LPS vs. LPS + EGCG, n = 3). (C) A total of 59 differentially S-nitrosylated protein spots were detected by NitroDIGE analysis (fold change > 1.3, P <0.05, LPS vs. LPS + EGCG, n = 3). (D) Seventy-eight proteins were identified from the above spots by LC-MS/MS, and SOD2 (a), PRDX (b), and USP14(c) were selected for validation by the BST method. After Biotin-HPDP labeling and biotin affinity pull-down, individual protein Western blotting was performed. The amount of SNO-proteins was quantified by a densitometer, normalized to total proteins, and expressed as percentage of untreated controls. Data are means ± SEM (n = 3); * P <0.05, untreated vs. LPS; # P <0.05, LPS vs. LPS + EGCG; ** P <0.05, untreated vs. EGCG. The results showed the down-regulation of S-nitrosylation levels of these proteins in “LPS + EGCG” compared to LPS-treated samples.
Figure 5Functional annotation and pathway analysis. (A) Three subsets of SNO-proteins with overlaps in between were identified from different treatments in this study. There are three common proteins shared by the three data sets, including TCP1, ISYNA1, and PRDX2. (B) Cellular location of the 78 SNO-proteins responding to EGCG treatment in LPS-stimulated BV-2 cells. (C) The top protein interaction network associated with EGCG-treatment in LPS-stimulated BV-2 cells was predicted by IPA and presented. Twenty-four SNO-proteins are involved in this network. The intensity of green color indicates the level of down-regulation. (D) Top 10 IPA canonical pathways targeted by EGCG in LPS-stimulated BV-2 cells.
IPA annotation of the top canonical pathways altered by EGCG in LPS-stimulated BV-2 cells
| NRF2-mediated oxidative stress response | 1.9E-11 | 11/192 (0.057) | ACTB, AKR1A1, CLPP, ERP29, GSTO1, HMOX1, PRDX1, SOD1, SOD2, STIP1, USP14 |
| Protein ubiquitination pathway | 2.6E-05 | 7/268 (0.026) | HSPA5, HSPA8, HSPD1, PSMA1, PSMB2, PSMD7, USP14 |
| Valine degradation I | 0.00022 | 3/35 (0.086) | DBT, DLD, HIBCH |
| Superoxide radicals degradation | 0.00031 | 2/8 (0.25) | SOD1, SOD2 |
| Branched-chain α-Keto acid dehydrogenase complex | 0.0004 | 2/9 (0.222) | DBT, DLD |
Notes: A ratio indicates the number of identified differentially S-nitrosylated proteins map to the pathway divided by the total number of proteins that exist in the pathway.
IPA annotation of molecular and cellular functions for the action of EGCG in LPS-stimulated BV-2 cells
| Free radical scavenging | 1.56E-09 – 1.38E-02 | 9 | ACTB, ALDH2, ANXA1, HMOX1, PRDX1, PRDX2, PRDX3, SOD1, SOD2 |
| Post-translational modification | 9.96E-09 – 1.01E-02 | 15 | ACADL, ALDH2, ERP29, GLUD1, HMOX1, HPRT1, HSPA5, HSPA8, HSPD1, IMPDH2, LRPAP1, P4HB, SOD1, SOD2, TCP1 |
| Protein folding | 9.96E-09 – 3.37E-03 | 7 | ERP29, HSPA5, HSPA8, HSPD1, LRPAP1, P4HB, TCP1 |
| Nucleic acid metabolism | 1.78E-07 – 1.67E-02 | 17 | ALDH2, ATIC, ATP5A1, CMPK2, HMOX1, HPRT1, HSPA5, HSPA8, HSPD1, IMPDH2, MTAP, PKM, RUVBL1, SOD1, SOD2, TALDO1, UMPS |
| Small molecule biochemistry | 4.34E-07 – 1.67E-02 | 34 | ACADL, AKR1A1, ALDH2, ANXA1, ATIC, ATP5A1, CMPK2, DLD, FABP5, GLUD1, GNPDA1, GSTO1, HMOX1, HPRT1, HSPA5, HSPA8, HSPD1, IMPDH2, LGALS1, MTAP, MVD, P4HB, PDIA3, PHGDH, PKM, PRDX1, PRDX2, PRDX3, RUVBL1, SOD1, SOD2, TALDO1, TIMM50, UMPS |